Jerad Suresh | Molecular Pharmacology | Research Excellence Award

Research Excellence Award

Jerad Suresh
Christian Medical College, India

Jerad Suresh
Affiliation Christian Medical College
Country India
Scopus Author ID 57193060944
Documents 10
Citations 262
h-index 5
Subject Area Molecular Pharmacology
Event International Molecular Biologist Awards
ORCID 0000-0001-5720-247X
Google Scholar 6XQYERYAAAAJ

Jerad Suresh is a researcher affiliated with Christian Medical College, India, whose stated subject area is Molecular Pharmacology. This discipline investigates the molecular mechanisms through which drugs and other chemical agents interact with biological systems, contributing to the understanding of drug action, therapeutic responses, and the development of pharmacological approaches. [1] [2]

Abstract

This article presents an academic profile of Jerad Suresh, affiliated with Christian Medical College, India, in the subject area of Molecular Pharmacology. The supplied bibliometric information identifies 10 documents, 262 citations, and an h-index of 5. These indicators provide a quantitative overview of scholarly publication and citation activity, although they do not independently establish the scientific quality, originality, or clinical significance of individual research contributions. [1] [2]

Molecular pharmacology examines the interactions between therapeutic compounds and biological molecules, including receptors, enzymes, ion channels, and intracellular signaling components. The field contributes to understanding pharmacological mechanisms and the molecular basis of therapeutic effects. This profile outlines the research context, scholarly indicators, and considerations relevant to evaluating research excellence while avoiding unsupported claims about specific experimental findings.

Keywords

Jerad Suresh; Research Excellence Award; Molecular Pharmacology; pharmacological research; molecular mechanisms; drug action; receptor signaling; scholarly publications; citation analysis; research impact; academic recognition; India.

Introduction

Molecular pharmacology is an interdisciplinary scientific field that investigates how drugs and biologically active compounds interact with molecular targets. It examines the mechanisms underlying drug-receptor interactions, enzyme regulation, cellular signaling, and changes in biological function following pharmacological intervention. These investigations provide a scientific foundation for understanding therapeutic responses and the development of pharmacological strategies. [4]

Research in this discipline may involve biochemical experiments, molecular and cellular techniques, pharmacological assays, and computational approaches. The interpretation of findings requires careful consideration of experimental design, biological relevance, reproducibility, and the limitations of the methods employed. Scholarly evaluation should consider both the quality of published research and its contribution to existing scientific knowledge. [3] [4]

Research Profile

Jerad Suresh is associated with Christian Medical College in India. His stated subject area is Molecular Pharmacology, a discipline concerned with the molecular basis of drug action and the biological pathways involved in pharmacological responses. The supplied Scopus author identifier is 57193060944, while the ORCID iD is 0000-0001-5720-247X. These identifiers provide access points for locating and reviewing scholarly records associated with the researcher. [1] [5]

A comprehensive description of an individual researcher’s specialization requires examination of the titles, abstracts, methodologies, and findings of their published work. Without a verified publication-level research summary, specific therapeutic targets, disease areas, experimental models, or drug-development achievements cannot be reliably attributed to this researcher.

Research Contributions

Research contributions in molecular pharmacology may advance understanding of how biological molecules respond to pharmacological agents. Investigations in this field can help clarify the relationships between molecular targets, cellular pathways, drug efficacy, and biological responses. The significance of an individual contribution depends on the originality of the research question, the reliability of the experimental evidence, and the relevance of the findings to the wider scientific community.

A publication-based assessment of research contributions may consider the following dimensions:

  • Originality and scientific relevance of the research questions addressed.
  • Investigation of molecular targets, pharmacological mechanisms, and biological interactions.
  • Reliability of experimental methods, data analysis, and interpretation.

These dimensions provide a general framework for evaluating molecular pharmacology research. The identification of specific contributions by Jerad Suresh requires examination of his verified publications and their associated research outcomes. [3] [4]

Publications

The supplied Scopus profile reports 10 documents associated with Jerad Suresh. This publication count represents the information provided for this academic profile and should be verified against the current Scopus author record. Differences between bibliographic databases may arise from indexing coverage, author-name variations, document classifications, and profile corrections. [1]

The researcher’s Google Scholar profile is also provided as a supplementary resource for exploring scholarly publications and citation records. The combination of Scopus and Google Scholar can assist readers in locating indexed research outputs and reviewing citation activity. Individual records should be checked for accurate authorship, journal details, publication dates, and document identifiers before being included in formal bibliographies. [2]

Research Impact

The supplied bibliometric information reports 262 citations and an h-index of 5 for Jerad Suresh, alongside 10 documents. Citation counts reflect references made by other publications to a researcher’s indexed work, while the h-index combines publication output and citation frequency. These indicators can contribute to a quantitative overview of scholarly activity but should not be interpreted as comprehensive measures of research quality or practical impact. [1] [2]

The h-index was introduced as a measure that combines the number of publications with the number of citations received. A researcher has an h-index of h when at least h publications have each received at least h citations. Although useful as one component of research assessment, the metric does not directly measure originality, experimental quality, clinical relevance, or broader societal benefit. [3]

Award Suitability

The Research Excellence Award recognizes the importance of scientific contributions, scholarly achievement, and research quality. Within the International Molecular Biologist Awards, an academic profile may provide relevant background information for understanding a candidate’s research activity. However, a researcher’s bibliometric indicators or inclusion in a profile should not, by themselves, be interpreted as confirmation of award selection or receipt.

An objective evaluation of Jerad Suresh’s suitability for research recognition may consider the following aspects:

  1. Originality and significance of documented contributions to molecular pharmacology.
  2. Scientific quality and methodological reliability of published research.

Conclusion

Jerad Suresh is identified in the supplied academic information as a researcher affiliated with Christian Medical College, India, with Molecular Pharmacology listed as his subject area. His reported scholarly profile includes 10 documents, 262 citations, and an h-index of 5. The supplied Scopus and ORCID identifiers provide resources for locating and examining his associated academic records.

References

  1. Elsevier. (n.d.). Scopus author details: Jerad Suresh, Author ID 57193060944.
    https://www.scopus.com/authid/detail.uri?authorId=57193060944
  2. Google Scholar. (n.d.). Jerad Suresh: Google Scholar author profile.
    https://scholar.google.com/citations?user=6XQYERYAAAAJ&hl=en
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569โ€“16572.
    https://doi.org/10.1073/pnas.0507655102
  4. Katzung, B. G., & Vanderah, T. W. (eds.). (2021). Basic and Clinical Pharmacology (15th ed.).
    https://accessmedicine.mhmedical.com/book.aspx?bookID=2988
  5. ORCID. (n.d.). Jerad Suresh researcher identifier: 0000-0001-5720-247X. ORCID. Public researcher identifier and associated record.
    https://orcid.org/0000-0001-5720-247X

ChongChao Yang | Molecular Pharmacology | Best Researcher Award

Dr. ChongChao Yang | Molecular Pharmacology | Best Researcher Award

Dr. ChongChao Yang at Nanjing Medical University, China.

Dr. Chong-chao Yang is currently pursuing his Ph.D. in Ophthalmology at Nanjing Medical University, China. ๐Ÿ“ With a keen focus on ocular neovascularization, Dr. Yang’s work dives deep into the mechanisms and therapeutic interventions for retinal diseases, particularly those associated with diabetes. His scientific rigor and precision are reflected in several publications in reputed SCI journals. ๐Ÿ”ฌ Among his noted achievements is the receipt of the prestigious National Scholarship for Doctoral Students, which highlights his academic excellence. Dr. Yang not only conceptualizes innovative research frameworks but also leads experiments, analyses, and manuscript writing. ๐Ÿงช His interdisciplinary approach combines molecular pharmacology with natural compound therapeutics, particularly studying the anti-angiogenic effects of sclareol. Known for his dedication, Dr. Yang is committed to advancing retinal research and translating scientific findings into therapeutic strategies that can impact global ophthalmic care. ๐ŸŒ

Professional Profile

Scopus

ORCID

๐ŸŽ“ Education

Dr. Chong-chao Yang began his academic journey with a strong foundation in medical sciences and later advanced into ophthalmic research. He is currently a Ph.D. candidate in Ophthalmology at Nanjing Medical University, one of Chinaโ€™s premier medical institutions. ๐Ÿซ His education centers around a combination of biomedical sciences, ophthalmic pathology, and molecular pharmacology, enabling a deep understanding of the visual system at both the anatomical and biochemical levels. He has built a solid theoretical and practical base in multi-omics, angiogenesis, and drug metabolism, all critical for his work in retinal neovascularization. ๐Ÿ“– With a methodical academic pathway and a thirst for innovation, Dr. Yang has consistently ranked among the top of his cohort and earned notable academic honors. His current Ph.D. research not only reflects academic excellence but also responds to urgent medical challenges associated with diabetic retinopathy and age-related eye disorders. ๐Ÿ‘๏ธโ€๐Ÿ—จ๏ธ

๐Ÿงช Experience

Chong-chao Yang has acquired significant experience in translational ophthalmic research, with a focus on angiogenesis and retinal pharmacokinetics. His academic and laboratory training has equipped him with comprehensive skills in experimental design, in vivo/in vitro assays, and bioinformatics-based molecular analysis. ๐Ÿ” During his Ph.D., he led an innovative project exploring the anti-angiogenic effects of sclareol, a plant-derived natural compound, using multi-omics platforms and pharmacokinetic profiling. ๐Ÿ’Š Dr. Yangโ€™s responsibilities extended from designing research protocols to data interpretation and manuscript preparation. He actively collaborated with clinicians and fellow researchers, reflecting his ability to merge experimental science with clinical relevance. ๐Ÿงซ His published meta-analysis on retinal microvasculature in amblyopic eyes and work on metabolite links with diabetic retinopathy further showcase his diverse research capabilities. His passion, diligence, and scientific vision make him a promising future leader in ocular pharmacology. ๐ŸŒฑ

๐Ÿ”ฌ Research Interests

Dr. Yangโ€™s research interests lie at the intersection of ocular neovascularization, angiogenesis, pharmacokinetics, and natural product pharmacology. His primary focus is to uncover the molecular mechanisms driving pathological blood vessel formation in the retina and to evaluate natural compounds, such as sclareol, as potential anti-angiogenic agents. ๐ŸŒฟ He employs a combination of Mendelian randomization, multi-omics techniques, and in vivo pharmacokinetic assays to understand how these agents work at cellular and systemic levels. His studies have explored novel insights into retinal microvascular remodeling, aiming to translate preclinical findings into therapeutic applications for diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. ๐Ÿง  In addition, he is increasingly interested in how metabolomic profiles relate to retinal disorders, which may guide personalized medicine in ophthalmology. Through cutting-edge research methodologies and interdisciplinary collaboration, Dr. Yang seeks to bridge molecular discoveries with real-world clinical solutions. ๐Ÿ’ก

๐Ÿ† Awards

Dr. Chong-chao Yang has been recognized for his academic brilliance and research excellence throughout his Ph.D. journey. His most distinguished honor is the National Scholarship for Doctoral Students, a prestigious award granted to top-performing students across China. ๐ŸŽ“ This award reflects his outstanding contributions to scientific research and academic excellence. Furthermore, Dr. Yang has consistently received departmental recognition for his publication output, research innovation, and scientific integrity. His participation in international journals such as Frontiers in Endocrinology and Ophthalmic Research has amplified his reputation as a young and promising researcher. ๐Ÿ… He has also been nominated for early-career research awards, with several of his peers and mentors praising his original work in ocular pharmacology and retinal biology. As he continues to contribute to the field of ophthalmology, Dr. Yang is a strong contender for awards in both national and international scientific forums. ๐ŸŒ

๐Ÿ“šTop Noted Publications

1. Yang, C.-C., Jiang, Q., & Xue, J.-S. (2024).

Title: Comprehensive multi-omics and pharmacokinetics reveal sclareol’s role in inhibiting ocular neovascularization
Journal: Phytomedicine
Link: ScienceDirect (exact link not provided)
Cited by: 0

Summary:
This study investigates the anti-angiogenic effects of sclareol, a plant-derived diterpene alcohol, using a multi-omics approach (including transcriptomics, proteomics, and metabolomics) combined with pharmacokinetic analysis. The authors identify key molecular pathways influenced by sclareol, especially those linked to VEGF signaling and oxidative stress, which are implicated in ocular neovascularizationโ€”a hallmark of diseases such as age-related macular degeneration and diabetic retinopathy. The findings demonstrate sclareolโ€™s ability to inhibit pathological blood vessel formation in the eye, suggesting its potential as a therapeutic agent in ophthalmology.

2. Yang, C.-C., et al. (2023).

Title: Causal relationships between blood metabolites and diabetic retinopathy: a two-sample Mendelian randomization study
Journal: Frontiers in Endocrinology, 14, 1213434
Link: Frontiers (exact link not provided)
Cited by: 3

Summary:
Using two-sample Mendelian randomization (MR), this paper explores the causal links between circulating blood metabolites and diabetic retinopathy (DR). Data from large-scale GWAS and metabolomics repositories were analyzed to identify metabolites that are not just associated with DR, but causally implicated. Several metabolites related to lipid metabolism and inflammation were found to significantly increase the risk of DR. The study highlights potential biomarkers and therapeutic targets for early intervention in DR, with implications for precision medicine approaches.

3. Yang, C.-C., et al. (2023).

Title: Analysis of Retinal Microvasculature Features in Amblyopic Eyes: A Meta-Analysis
Journal: Ophthalmic Research, 66(2), 155โ€“162
Link: Karger (exact link not provided)
Cited by: 5

Summary:
This meta-analysis synthesizes data from multiple optical coherence tomography angiography (OCTA) studies to assess retinal microvascular changes in amblyopic eyes. The findings suggest significant reductions in vessel density and perfusion in amblyopic eyes compared to controls, particularly in the superficial vascular plexus. These results offer new insights into the vascular mechanisms underlying amblyopia and suggest that microvascular features may serve as diagnostic or monitoring biomarkers in amblyopia management.

Conclusion

Based on the evidence provided, Chong-chao Yang is a promising early-career researcher with a solid academic foundation, innovative focus, and active contribution to the field of ophthalmology. His clear research trajectory, publication in SCI-indexed journals, and national recognition make him a credible and deserving nominee for the Best Researcher Award, especially in the early career or emerging researcher category.